Novo Nordisk insists its decision is unrelated to pressure from the US president
Novo Nordisk insists its decision is unrelated to pressure from the US president
Copy link
Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance
Fierce competition and threat of Trump tariffs lead to Danish company cutting costs
The announcements come days after President Donald Trump struck deals with Novo Nordisk and Eli Lilly to make their GLP-1s easier…
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition
Patients can pay $499 in cash per month for three dose sizes of Ozempic through the company's direct-to-consumer pharmacy and…
US administration is in negotiations over cost of Danish group’s best-selling obesity drug
Diabetes drug Ozempic will cost half-price for US patients paying cash
